Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome.
暂无分享,去创建一个
N. Beeching | A. Breckenridge | D. Back | M. Barry | F. Mulcahy | C. Bergin | F. Nye | J. Howe | S. Ormesher
[1] P. Volberding,et al. Combination Therapy with Zidovudine and Didanosine Compared with Zidovudine Alone in HIV-1 Infection , 1993, Annals of Internal Medicine.
[2] N. Beeching,et al. Metabolism of didanosine (ddI) by erythrocytes: pharmacokinetic implications. , 1993, British Journal of Clinical Pharmacology.
[3] N. Beeching,et al. The effects of indomethacin and naproxen on zidovudine pharmacokinetics. , 1993, British journal of clinical pharmacology.
[4] J. Gallo,et al. Pharmacokinetic Evaluation of anti-HIV Drug Interactions: Effect of Zidovudine on 2′-3′-Dideoxyinosine Kinetics in Monkeys , 1993 .
[5] M. Shelton,et al. Comparative Pharmacokinetics of Antiviral Nucleoside Analogues , 1993, Clinical pharmacokinetics.
[6] J. Groopman,et al. Nucleoside therapy for HIV infection--some answers, many questions. , 1992, The New England journal of medicine.
[7] R. Diasio,et al. Clinical pharmacokinetics of 3′‐azido‐3′‐deoxythymidine (zidovudine) and catabolites with formation of a toxic catabolite, 3′‐amino‐3′‐deoxythymidine , 1992, Clinical pharmacology and therapeutics.
[8] M. Wientjes,et al. Lack of pharmacokinetic interaction between intravenous 2',3'-dideoxyinosine and 3'-azido-3'-deoxythymidine in rats , 1992, Antimicrobial Agents and Chemotherapy.
[9] C. T. Viswanathan,et al. Pharmacokinetic evaluation of drug interactions with anti-HIV drugs, II: Effect of 2',3'-dideoxyinosine (ddI) on zidovudine kinetics in monkeys. , 1992, AIDS research and human retroviruses.
[10] S D Kemp,et al. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. , 1991, Science.
[11] C. Metroka,et al. Failure of prophylaxis with dapsone in patients taking dideoxyinosine. , 1991, The New England journal of medicine.
[12] A. Breckenridge,et al. The effect of various drugs on the glucuronidation of zidovudine (azidothymidine; AZT) by human liver microsomes. , 1991, British journal of clinical pharmacology.
[13] F. Valentine,et al. Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome—related complex , 1991, Clinical pharmacology and therapeutics.
[14] H. Mitsuya,et al. Antiretroviral Therapy in AIDS , 1990 .
[15] D. Richman,et al. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. , 1989, Science.
[16] J. Falloon,et al. The pharmacokinetics of zidovudine administered by continuous infusion in children. , 1989, Annals of internal medicine.
[17] A. Fauci,et al. The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. , 1988, Science.
[18] M A Fischl,et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. , 1987, The New England journal of medicine.
[19] B. Evatt,et al. Thermal inactivation of the acquired immunodeficiency syndrome virus, human T lymphotropic virus-III/lymphadenopathy-associated virus, with special reference to antihemophilic factor. , 1985, The Journal of clinical investigation.
[20] R. Pugh,et al. Transection of the oesophagus for bleeding oesophageal varices , 1973, The British journal of surgery.
[21] N. Beeching,et al. Zidovudine pharmacokinetics in zidovudine-induced bone marrow toxicity. , 1994, British journal of clinical pharmacology.
[22] S. Lagakos,et al. Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. , 1990, Journal of acquired immune deficiency syndromes.